Sep 16, 2024 7:00am EDT Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Aug 29, 2024 8:15am EDT Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Aug 08, 2024 7:01pm EDT Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
Jul 11, 2024 7:00am EDT Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
Jul 01, 2024 7:00am EDT Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
Jun 28, 2024 7:00am EDT Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
Jun 24, 2024 7:00am EDT Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
Jun 10, 2024 7:00am EDT Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
